Aquatic Animal Antibiotic Detection Using DNA Methylation Profiles

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for detecting antibiotic and chemical use in aquatic animals are inadequate, as they rely on residue testing in blood or tissues, which fails to capture all antibiotic classes, especially those added to feed or water, and lack a means to assess historical usage.

Innovation Solution

Utilize DNA methylation patterns to detect antibiotic and chemical use by comparing the methylation status of CpG sites in test animals to a reference, identifying hypomethylation or hypermethylation as indicators of antibiotic and chemical exposure.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If residue testing in blood or tissues is used to detect antibiotic use, then current antibiotic residues can be detected, but historical antibiotic use cannot be assessed and many antibiotic classes are missed

Engineering Contradiction:
Improvedetection accuracyVSAvoidhistorical usage information
Core Design Contradiction:
Measurement precisionVSLoss of information

Solution Approach 1:

The patent uses DNA methylation patterns as an intermediary biomarker that indirectly records antibiotic exposure history. Instead of directly detecting antibiotic residues, the method detects epigenetic modifications (methylation status of CpG sites) that serve as a persistent record of past antibiotic exposure, thereby recovering historical usage information that direct residue testing cannot provide

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the chemical detection mechanism (residue testing) with a biological epigenetic marker detection mechanism. By substituting direct chemical analysis with analysis of DNA methylation patterns, the method achieves both broader coverage of antibiotic classes and the ability to detect historical exposure, as methylation patterns persist long after antibiotic residues have degraded

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If chemical assays are used to test for antibiotic residues, then presence of antibiotics in blood or tissues can be detected, but usage of antibiotics added to feed or water is not captured

Engineering Contradiction:
Improvedetection reliabilityVSAvoidcoverage of antibiotic classes
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent creates a universal detection method that works across all antibiotic classes by targeting the common biological response (DNA methylation changes) rather than detecting specific chemical structures. This single epigenetic-based approach can identify exposure to any antibiotic that induces methylation changes, making the method universally applicable to all antibiotic classes without requiring class-specific assays

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The method uses DNA methylation patterns as a universal intermediary marker that translates diverse antibiotic exposures into a common detectable signal. Different antibiotic classes may cause different specific methylation changes, but they all produce detectable epigenetic markers, allowing a single detection platform to cover multiple antibiotic classes that would otherwise require separate chemical assays

Inventive Principle:
Principle #24Intermediary (Mediator)

3Loss of time

If no epigenetic markers are analyzed, then current antibiotic use can be detected via residues, but past antibiotic exposure cannot be determined

Engineering Contradiction:
Improvedetection time windowVSAvoidexposure assessment accuracy
Core Design Contradiction:
Loss of timeVSMeasurement precision

Solution Approach 1:

The patent applies preliminary action by detecting epigenetic markers that are established during antibiotic exposure and persist long after the exposure ends. The methylation patterns are formed during the antibiotic treatment period and serve as a lasting record, allowing detection well after the actual exposure event, thereby extending the detectable time window backward in time

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The method detects more than just current antibiotic presence by capturing historical exposure information through persistent epigenetic markers. The methylation changes serve as an exaggerated or extended signal that persists beyond the normal detection window of residue testing, providing excessive information about past exposure that enhances the time window for detection

Inventive Principle:
Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides a simple and accurate method to detect current and past antibiotic and chemical use in aquatic animals, differentiating between therapeutic and prophylactic use, and predicting potential adverse effects on animal welfare and production sustainability.

Implementation Method 1

DNA methylation patterns are modified along the life of an individual by environmental forces like diet, stress, drugs, or pollution among many others

Methodology Applied
Scientific EffectDNA methylation:

Data Source

PatentUS20250320565A1Detecting antibiotic and/or chemical use in aquatic animals using epigenetic means
Publication Date: 2025.10.16 EVONIK OPERATIONS GMBH
  • US20250320565A1 patent drawing
  • US20250320565A1 patent drawing

AI summary

A method of determining if an aquatic test animal and/or test animal from which a product is derived has been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical includes: (a) determining a test methylation profile from genomic material contained in a biological sample obtained from the test animal and/or animal-derived product; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal, where the control animal was not treated and/or is not currently undergoing treatment with at least one antibiotic and/or veterinary chemical, wherein a difference in the test methylation profile of (a) compared to the reference methylation profile from the control animal is indicative of the test animal having been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical.